`Q9983` Florbetaben f18 diagnostic

Florbetaben f18, diagnostic, per study dose, up to 8.1 millicuries

Medicare coverage: Special coverage instructions apply
Status: active (October 2026 file)

Medically Unlikely Edits (effective October 1, 2026)

Practitioner: max 1 units per day (clinical), rationale: Nature of Service/Procedure
Outpatient hospital: max 1 units per day (clinical), rationale: Nature of Service/Procedure

Medicare pricing for Q9983

Physician Fee Schedule (CY 2026, RVU26D)

Status E: excluded from the PFS by regulation.

Payer policies and prior authorization for Q9983

Payer coverage policies that name Q9983

Q9983 appears in 2 coverage policies from Aetna, Blue Cross & Blue Shield of Mississippi.

Payer	Policy	Role in policy	Reviewed	Document
Aetna	Positron Emission Tomography (PET) (0071)	covered if criteria are met	Sep 14, 2026	payer document
Blue Cross & Blue Shield of Mississippi	Selected Positron Emission Tomography Technologies For Evaluation Of Alzheimer Disease	listed, no stance		payer document

Medicaid fee-for-service

Prior authorization required or conditional in IN.

AZ: $1505.44 (asc), effective Oct 1, 2026
KY: $1584.67 (asc), effective Jan 1, 2026
MS: $1584.67 (comprehensive), effective Jul 1, 2026
ND: $0.00 (physician), effective Aug 1, 2026
OK: $1396.75 (outpatient_hospital_apc), effective Jan 1, 2026
VT: $0.00 (outpatient_hospital_opps), effective Feb 1, 2026
WY: $685.94 (outpatient_hospital_apc, Ambulatory Surgical Centers), effective Apr 1, 2026

From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.

Q9983 Florbetaben f18 diagnostic